DK4013756T3 - MLL1-inhibitorer og anticancermidler - Google Patents
MLL1-inhibitorer og anticancermidler Download PDFInfo
- Publication number
- DK4013756T3 DK4013756T3 DK20781093.8T DK20781093T DK4013756T3 DK 4013756 T3 DK4013756 T3 DK 4013756T3 DK 20781093 T DK20781093 T DK 20781093T DK 4013756 T3 DK4013756 T3 DK 4013756T3
- Authority
- DK
- Denmark
- Prior art keywords
- mll1
- inhibitors
- anticancer agents
- anticancer
- agents
- Prior art date
Links
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 title 1
- 101001045846 Homo sapiens Histone-lysine N-methyltransferase 2A Proteins 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019107010 | 2019-09-20 | ||
| CN2020095916 | 2020-06-12 | ||
| PCT/IB2020/058735 WO2021053617A1 (en) | 2019-09-20 | 2020-09-18 | Mll1 inhibitors and anti-cancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4013756T3 true DK4013756T3 (da) | 2024-05-27 |
Family
ID=72659833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20781093.8T DK4013756T3 (da) | 2019-09-20 | 2020-09-18 | MLL1-inhibitorer og anticancermidler |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220380371A1 (da) |
| EP (1) | EP4013756B1 (da) |
| JP (1) | JP7344372B2 (da) |
| KR (1) | KR20220050963A (da) |
| CN (1) | CN114981270A (da) |
| AU (1) | AU2020350211B2 (da) |
| CA (1) | CA3154136A1 (da) |
| DK (1) | DK4013756T3 (da) |
| IL (1) | IL291396A (da) |
| WO (1) | WO2021053617A1 (da) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0314761A (pt) * | 2002-09-27 | 2005-07-26 | Sumitomo Pharma | Composto de adenina e seu uso |
| BR112015031073B1 (pt) * | 2013-06-21 | 2022-11-29 | Zenith Epigenetics Ltd | Compostos inibidores bicíclicos de bromodomínio e composição farmacêutica contendo os referidos compostos |
| TWI703150B (zh) * | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| CA3036987A1 (en) * | 2016-09-16 | 2018-03-22 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
-
2020
- 2020-09-18 KR KR1020227009462A patent/KR20220050963A/ko not_active Application Discontinuation
- 2020-09-18 EP EP20781093.8A patent/EP4013756B1/en active Active
- 2020-09-18 WO PCT/IB2020/058735 patent/WO2021053617A1/en unknown
- 2020-09-18 US US17/761,902 patent/US20220380371A1/en active Pending
- 2020-09-18 DK DK20781093.8T patent/DK4013756T3/da active
- 2020-09-18 CA CA3154136A patent/CA3154136A1/en active Pending
- 2020-09-18 CN CN202080065701.7A patent/CN114981270A/zh active Pending
- 2020-09-18 JP JP2022516416A patent/JP7344372B2/ja active Active
- 2020-09-18 AU AU2020350211A patent/AU2020350211B2/en active Active
-
2022
- 2022-03-15 IL IL291396A patent/IL291396A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220050963A (ko) | 2022-04-25 |
| EP4013756A1 (en) | 2022-06-22 |
| CN114981270A (zh) | 2022-08-30 |
| WO2021053617A1 (en) | 2021-03-25 |
| AU2020350211A1 (en) | 2022-04-07 |
| EP4013756B1 (en) | 2024-05-08 |
| AU2020350211B2 (en) | 2023-08-17 |
| JP2022548618A (ja) | 2022-11-21 |
| US20220380371A1 (en) | 2022-12-01 |
| IL291396A (en) | 2022-05-01 |
| CA3154136A1 (en) | 2021-03-25 |
| JP7344372B2 (ja) | 2023-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288381A (en) | Tead inhibitors and their uses | |
| IL288384A (en) | Tead inhibitors and their uses | |
| DK3389658T3 (da) | Glycosidasehæmmere og anvendelser deraf | |
| DK3946464T3 (da) | Forbindelser og konjugater deraf | |
| DK3565550T3 (da) | Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan | |
| DK3380101T3 (da) | Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil | |
| DK3610005T3 (da) | Peptidligase og anvendelse deraf | |
| DK3482760T3 (da) | Kombination, der omfatter en ep4-antagonist og en immuncheckpoint-hæmmer | |
| IL276813A (en) | Arginase inhibitors | |
| DK3672976T3 (da) | Bcl-2-hæmmere | |
| DK3452485T3 (da) | Arginasehæmmere og deres terapeutiske anvendelser | |
| DK3536698T3 (da) | Lanosterol-prodrugforbindelse og anvendelse deraf | |
| DK3532459T3 (da) | Lsd1-hæmmere og medicinske anvendelser deraf | |
| DK3621694T3 (da) | Lrrc33-inhibitorer og anvendelse heraf | |
| DK3543240T3 (da) | URAT1-inhibitor og anvendelse deraf | |
| DK3753937T3 (da) | Atr-hæmmer og anvendelse deraf | |
| DK3582776T3 (da) | Piperidinsubstituerede mnk-hæmmere og dertil relaterede fremgangsmåder | |
| DK3571192T3 (da) | Jak1-selektive inhibitorer | |
| DK3268374T3 (da) | Kv1.3-inhibitorer og deres medicinske anvendelse | |
| DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
| DK3448955T3 (da) | Korrosionshæmmersammensætninger og fremgangsmåder til anvendelse deraf | |
| DK3677278T3 (da) | Isoformselektive tgfbeta1-inhibitorer og anvendelse deraf | |
| PT3712147T (pt) | Inibidor de sglts e sua aplicação | |
| DK3474883T3 (da) | Komplementinhibitorer og anvendelser deraf | |
| DK3947375T3 (da) | Imidazolonylquinolinforbindelser og terapeutiske anvendelser deraf |